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Gaucher Disease (GD) 
 Autosomal recessive 
 Lysosomal Storage Disorder
 Deficient enzyme: β-glucocerebrosidase (Gcase)
 Gene: GBA (1q21)
 Atypical form:
 Deficient enzyme: Saposin C
 Gene: PSAP (10q21-q22)
Original illustration by Marcos Bernardino for  
Cristiana Petriz´s “Gigi e a Doença de Gaucher”, 2010
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Gaucher Disease (GD) 
 Autosomal recessive 
 Lysosomal Storage Disorder
 Deficient enzyme: β-glucocerebrosidase (Gcase)
 Gene: GBA (1q21)
 One of the most frequent LSD
 Available ERT
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Gaucher Disease (GD) 
 “The prototype lysosomal disease…”
(Zhao and Grabowski, 2002)
 1st  described
 1st drug approved
 > nr therapeutic approaches
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Gaucher Disease (GD) 
 “The prototype lysosomal disease…”
(Zhao and Grabowski, 2002)
 Still…
it does have some significant differences
Original illustration by Marcos Bernardino for  
Cristiana Petriz´s “Gigi e a Doença de Gaucher”, 2010
At the populational level…
GBA mutation carriers Parkinson’s disease
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Objective
Understand the role of variations in SCARB2 in the
broad phenotype spectrum observed for GD patients
in the Portuguese population
Sample Collection
 Portuguese GD cohort
 91 samples
 Biochemically
 molecularly characterized GD patients, 
diagnosed at CGMJM 
from ? to 2013
+
 Controls
 50 samples 
 screening of the novel variants
Genetic analysis
 Sanger sequencing 
 12 SCARB2 exons + intronic bounderies
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Alu element 
 Intron 12 
 In silico nalyses
 Evaluation of the deleterious potential of the novel variant(s)
 DNA
 Peripheral blood
 Fibroblasts from patients’ skin biopsies 
Results
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Also present in the controls
Results
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high prevalence in the normal population
Results
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Reassessment of the clinical case
 Symptoms’ onset: 7 months 
 Disease progression:
 severe anemia; 




 marked splenomegaly; 
 interstitial lung disease with multiple recurrent infections; 
 bilateral convergent strabismus; 
 marked axial hypotonia
global psychomotor developmental delay
 2nd child of young         parents 
healthy 
unrelated
Cape Verdean origin 
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Reassessment of the GBA genotype
 Genotype: L444P/L444P
 Common mutation 
 Known genotype-phenotype correlation

 2nd child of young         parents 
healthy 
unrelated




therapeutic follow-up with assessment of chitotriosidase levels 

enzyme levels disparate from the ones 
expected for a GD patient under ERT
low response to treatment?




 Western Blot 
 Real time PCR 
 Immunofluorescence 
 GCase activity assay
p.T398M
A LOOK FORWARD…
 Functional studies 
 Western Blot 
 Real time PCR 
 Immunofluorescence 
 GCase activity assay
p.T398M
dysfunction or
reduction of LIMP-2 levels
Lower receptor density

key factor for recombinant GCase uptake
(Desnick and Schuchman, 2012)
A LOOK FORWARD…
Parkinson’s disease
Dementia with Lewy Bodies
 SCARB2 screening
 Portuguese cohort
is there an association?
A LOOK FORWARD…
Parkinson’s disease




 1st time a whole GD population is screened for SCARB2 mutations;

SCARB2 variability does not account much to the 
Portuguese GD phenotypic spectrum
Still, 
one novel variant here identified (p.T398M), deserves further attention and
extra studies
Plenty of questions remain unanswered…
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